Clinical Trials Logo

Antibiotic Resistant Infection clinical trials

View clinical trials related to Antibiotic Resistant Infection.

Filter by:

NCT ID: NCT04013737 Completed - Infection Clinical Trials

Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care

EPICIMPOC
Start date: February 28, 2017
Phase:
Study type: Observational

Antimicrobials (drugs that kill or stop the growth of microorganisms including bacteria, thereby treating infections) commonly used to treat patients with infections are becoming less effective over time as bacteria develop resistance to them. Antimicrobial usage itself can lead to development and spread of antimicrobial resistance. Antimicrobial resistance is now a major threat to patient safety. To conserve the effectiveness of antimicrobials the investigator need to develop ways to use them more sensibly healthcare professionals who diagnose and treat infections must be able to access antimicrobial guidelines and test results at the patient bedside. This needs to be provided rapidly and with support to make sure that the decisions on prescribing antimicrobials are the best that can be made.

NCT ID: NCT03980197 Recruiting - Clinical trials for Antibiotic Resistant Infection

Strategy to Prevent Transmission of Multidrug-resistant Gram-negative Organisms in ICU

Start date: June 3, 2019
Phase: N/A
Study type: Interventional

1. Objective of study The purpose of this study was to investigate whether the active surveillance and preemptive isolation of multidrug-resistant Gram-negative bacteria in the intensive care unit affected the reduction of the rate of acquisition of multidrug- resistant Gram-negative bacteria (MDRGNB). 2. Background Treatment option for MDRGNB (Carbapenem-resistant P. aeruginosa, Carbapenem-resistant A. baumannii, Carbapenem-resistant Enterobacteriaceae) is limited. Development of infection due to MDRGNB is common in ICU. Strategy to prevent transmission of MDRGNB is needed, and there is two approaches; First, antimicrobial stewardship program, and second, infection control strategy.The investigators aimed to figure out the role of active surveillance test and preemptive isolation of MDRGNB in reduction of acquisition rate of MDRGNB. 3. Methods Pragmatic cluster randomized, crossover, controlled trial During first period (6 months), intervention group (randomized 3 ICUs) perform daily chlorhexidine bathing, active surveillance test and preemptive isolation and contact precaution. Control group (randomized 3 ICUs) perform standard precaution with daily chlorhexidine bathing, and start contact precaution when clinical isolates reveals MDRGNB. After 1 month washout period, intervention group and control group cross over for next 6 months.

NCT ID: NCT03950544 Recruiting - Clinical trials for Antibiotic Resistant Infection

The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae

Start date: January 1, 2019
Phase: Early Phase 1
Study type: Interventional

The infection of carbapenem resistant klebsiella pneumoniae (CRKP) is increasingly serious.Based on the early experimental basis and relevant research background,this study intends to separate and purify the CRKP from the bronchoalveolar lavage fluid (BALF) of the clinical patients.Designed by checkerboard assay and time-kill assay(TKA),this study can explore the best combination therapy based on carbapenems.

NCT ID: NCT03866291 Completed - Clinical trials for Antibiotic Resistant Infection

ESBL in Patients Returning to Sweden With Traveller's Diarrhoea

Start date: February 1, 2017
Phase:
Study type: Observational

Patients with traveller's diarrhoea frequently harbour Extended Spectrum Betalactamase (ESBL)-producing Enterobacteriaceae (EPE) returning from EPE-endemic areas. This study investigates to what extent travellers returning to Sweden with traveller's diarrhoea carry ESBL in their stool. The isolates are examined further according to species, phenotype, antibiogram and whole genome sequencing.

NCT ID: NCT03865706 Active, not recruiting - Sepsis Clinical Trials

Inulin for Infections in the Intensive Care Unit

Start date: October 14, 2019
Phase: Phase 2
Study type: Interventional

Normal gut bacteria prevent colonization and subsequent infection with MDR organisms (MDROs) through competition for resources and other mechanisms. During critical illness, this function of the microbiome is lost and there are no current treatments to restore it. Preliminary data indicates that the prebiotic fiber inulin is safe and may alter the gastrointestinal microbiome to improve gut barrier function, decrease colonization with MDROs, and reduce downstream risk for intensive care unit (ICU)-acquired MDR infections. However, the impact of inulin during critical illness is unknown. This double-blind, randomized clinical trial will test inulin for the prevention of antibiotic resistant infections in the ICU. The trial's specific aims are to determine (1) the feasibility, tolerability, and safety of inulin in the intensive care unit; (2) the impact of inulin on gut colonization with antibiotic-resistant pathogens; and (2A/exploratory) the impact of inulin on ICU-acquired antibiotic-resistant infections.

NCT ID: NCT03860415 Completed - Clinical trials for Antibiotic Resistant Infection

Can Probiotic Vivomixx Eradicate Colonization With ESBL?

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Can probiotic Vivomixx eradicate Extended Spectrum BetaLactam (ESBL) colonization in adult patients?

NCT ID: NCT03857295 Not yet recruiting - Clinical trials for Bacterial Infections

Infections Following NeuroSurgery (INS)

INS
Start date: March 11, 2019
Phase:
Study type: Observational

Neurosurgery (NS) is essential for the treatment of various diseases such as malignant tumors, vascular conditions, spinal stenosis or trauma. However, NS can be complicated by the onset of infections, directly related to surgery or to hospitalization. Little is known regarding the epidemiology, the optimal treatment regimens and the outcome of infections following NS (I-NS). The study aims at investigating the clinical and microbiological characteristics as well as the outcomes of I-NS occurring at a single Institution (IRCCS Neuromed, Pozzilli, Italy) during the period 2016-2018. Patients with at least 1 infective episode requiring antimicrobial therapy are included in this retrospective observational study.

NCT ID: NCT03855709 Not yet recruiting - Clinical trials for Antibiotic Resistant Infection

Antibiotic-resistant Bacterial Infection of Hepatic Patients

Start date: May 2019
Phase:
Study type: Observational

the investigators want to identify the microbial profile, antibiotic resistant bacteria in hepatic patients with infections in Liver ICU, and explore risk factors and outcomes in those patients with antibiotic resistant bacteria.

NCT ID: NCT03848091 Completed - Clinical trials for Antibiotic Resistant Infection

Prosthesis Infection and One-step Exchange: Pretreatment by Targeted Antibiotic Therapy in At-risk Patients

Start date: April 1, 2016
Phase:
Study type: Observational

One-step exchange arthroplasty is more and more used in the treatment of chronic infections, especially in patients at risk anesthetic. This strategy is not recommended in patients infected with multidrug-resistant organisms or difficult to treat because of a risk of bacterial persistence on the new implant. Antibiotic pretreatment by a narrow-spectrum molecule and for which resistance acquisition is difficult might be of interest to try to reduce the inoculum and avoid contamination of the new implant.

NCT ID: NCT03752476 Not yet recruiting - Clinical trials for Antibiotic Resistant Infection

Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

INOR Blact
Start date: January 1, 2019
Phase:
Study type: Observational

This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care It's retrospective case controle study. Cases are colonized patient by multidrug resistant bacteria hospitalized in intensive care during the fist hospitalization in intensive care. Temoin are patients with the same characteristics than case but no colonized by multidrug resistant bacteria.